• Molecular NamePaliperidone
  • Synonym9-Hydroxyrisperidone
  • Weight426.492
  • Drugbank_IDDB01267
  • ACS_NO144598-75-4
  • Show 3D model
  • LogP (experiment)2.39
  • LogP (predicted, AB/LogP v2.0)2.31
  • pka2.6, 8.2
  • LogD (pH=7, predicted)1.14
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-2.83
  • LogSw (predicted, AB/LogsW2.0)0.5
  • Sw (mg/ml) (predicted, ACD/Labs)0.05
  • No.of HBond Donors1
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds4
  • TPSA82.17
  • StatusFDA approved
  • AdministrationOral- extended release, long-acting, once-monthly IM injection
  • PharmacologyAn atypical antipsychotic
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability28.0
  • Protein binding74.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmFour primary metabolic pathways have been identified in vivo, none of which could be shown to account for more than 10% of the dose: dealkylation, hydroxylation, dehydrogenation, and benzisoxazole scission.
  • Half life23 h (oral)
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityAdverse events reported with frequency more than 10% include tachycardia, restlessness, headache, somnolence.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A